Clinical Trial

Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-08.
Trial Details
NCT Number NCT06818916
Lead Sponsor Beijing Children's Hospital
Conditions Delayed Platelet Engraftment, Neuroblastoma, Autologous Hematopoietic Stem Cell Transplantation
Enrollment 30 participants
Start Date 2024-06-30
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-03